Evercore analyst Gavin Clark-Gartner maintains $argenx SE (ARGX.US)$ with a buy rating, and maintains the target price at $706.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 22.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The continuation of Phase 3 across all three myositis subtypes is seen as a positive factor that could enhance future pipeline value, though it may not significantly impact stock movement immediately. The analysis included a 70% probability of success for myositis, with adjustments anticipated upon the release of full data at an upcoming medical conference.
Argenx's announcement about achieving clinical proof-of-concept in myositis with subQ efgart showing statistically significant improvement across all three evaluated myositis subtypes in Phase 2 has been positively noted. This development is seen as enhancing Argenx's position in the autoimmune sector, and detailed results are anticipated at a future medical conference.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
